Dynavax Technologies Co. (NASDAQ:DVAX)’s stock price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $4.30 and traded as high as $3.88. Dynavax Technologies shares last traded at $3.88, with a volume of 34,013 shares changing hands.
Several equities research analysts have recently commented on the stock. Cowen restated a “buy” rating on shares of Odonate Therapeutics in a research note on Monday, June 3rd. BidaskClub raised Xilinx from a “hold” rating to a “buy” rating in a report on Saturday, June 29th. Royal Bank of Canada reaffirmed a “buy” rating on shares of PrairieSky Royalty in a report on Friday, May 24th. ValuEngine cut Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, Cantor Fitzgerald raised Dynavax Technologies from a “neutral” rating to an “overweight” rating and set a $20.00 price target for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $16.81.
The company’s fifty day moving average price is $4.25. The company has a quick ratio of 4.61, a current ratio of 5.27 and a debt-to-equity ratio of 4.88. The firm has a market capitalization of $262.21 million, a price-to-earnings ratio of -1.58 and a beta of 0.67.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same period in the previous year, the business posted ($0.63) earnings per share. The firm’s revenue for the quarter was up 3294.1% compared to the same quarter last year. On average, equities research analysts predict that Dynavax Technologies Co. will post -2.13 earnings per share for the current fiscal year.
In related news, SVP Robert Coffman sold 32,218 shares of Dynavax Technologies stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $4.58, for a total value of $147,558.44. Following the completion of the transaction, the senior vice president now directly owns 132,470 shares of the company’s stock, valued at $606,712.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 4.90% of the company’s stock.
Large investors have recently made changes to their positions in the business. Advisor Group Inc. raised its holdings in Dynavax Technologies by 515.3% during the 4th quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 3,746 shares during the last quarter. Quantamental Technologies LLC bought a new stake in Dynavax Technologies during the 1st quarter worth about $62,000. Legal & General Group Plc raised its holdings in Dynavax Technologies by 18.7% during the 4th quarter. Legal & General Group Plc now owns 11,814 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,860 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Dynavax Technologies by 56,326.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock worth $95,000 after purchasing an additional 12,955 shares during the last quarter. Finally, Pearl River Capital LLC bought a new stake in Dynavax Technologies during the 1st quarter worth about $106,000. 81.94% of the stock is owned by hedge funds and other institutional investors.
Dynavax Technologies Company Profile (NASDAQ:DVAX)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Recommended Story: How is diluted EPS different from basic EPS?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.